Algerian Radio
Dr. Khadija Bouguerra, Quality Management Official at the National Agency for Pharmaceutical Products (ANPP), confirmed that Algeria has achieved significant progress in medicine production in recent years. She noted that the self-sufficiency rate for the national market's needs has reached 83%, with expectations of further increases thanks to ongoing projects and the policy adopted to support the pharmaceutical industry.
This progress is a practical embodiment of the President of the Republic of Algeria’s directives aimed at achieving pharmaceutical sovereignty and enhancing health security. This vision was further strengthened by the establishment of the Ministry of Pharmaceutical Industry in 2020, alongside the National Agency for Pharmaceutical Products becoming operational in the same year.
Algeria currently counts 233 medicine production units and factories. Additionally, the Ministry of Pharmaceutical Industry has approved licenses for 100 new projects currently under construction. This represents one-third of the pharmaceutical factories across the African continent.
Algeria possesses more than 780 production lines for various classes of medicine, including complex drugs. The same source emphasized that the country is the only nation in Africa and the Arab world to produce insulin pens 100% locally. Furthermore, Algeria manufactures approximately 54 types of cancer treatment drugs out of about 200 registered in the national formulary for combating the disease.
The licenses granted for new medicine production projects are expected to reflect positively on the labor market, especially with the registration of projects for innovative drugs, alongside a project to establish a biological research and vaccine production center. A new project with the Saidal Group was also announced in the field of cell therapy, which would enhance job opportunities and support innovation within the national pharmaceutical industry.
